Placebo effects do not negate the significant reduction of TG and non-inferior effect on LCL-C from baseline.
I have read the entire document and these are my conclusions. Hopefully Yahoo will allow me to past the entire thing this time:
Primary objective: ANCHOR’s primary objective was to determine the efficacy of AMR101 2g
daily and 4g daily, compared to placebo, in lowering fasting TG levels in patients at high risk for
cardiovascular disease and with fasting TG levels ≥ 200 mg/dL and